➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Colorcon
AstraZeneca
McKesson
Baxter

Last Updated: September 23, 2020

DrugPatentWatch Database Preview

Claims for Patent: 7,238,853

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,238,853
Title:Molecular mechanisms for gene containment in plants
Abstract: The present invention provides a molecular mechanism for gene containment in sexually reproducing transgenic plants. The mechanism is achieved with a molecular construct comprising a blocking construct (BC) that is inserted fully or partially into an intron of a transgene of interest (TGI). The TGI encodes desired gene products, such as heterologous or homologous proteins, peptides or other useful products. The expression of the BC leads to block of at least one molecular or physiological function that is essential for development or reproduction of the transgenic plant. Thereby the BC expression leads to death or incapacity of sexual reproduction of the plant. Moreover, the mechanism comprises an externally applicable recovering tool to recover the functions blocked by the BC. The recovering tool may be a recovering construct (RC).
Inventor(s): Kuvshinov; Viktor (Helsinki, FI), Koivu; Kimmo (Helsinki, FI), Kanerva; Anne (Helsinki, FI), Anissimov; Andrei (Helsinki, FI)
Assignee: Unicrop Ltd (Helsinki, FI)
Application Number:10/644,664
Patent Claims:1. A molecular mechanism for gene containment in sexually reproducing transgenic plants by providing a plant with a recoverable block of function (RBF) system, said system comprising: a transgene of interest (TGI) encoding desired gene products; a blocking construct (BC) having a capacity to block at least one molecular or physiological function essential for development or reproduction of the transgenic plant, thereby leading to death or incapacity of sexual reproduction, said BC being fully inserted into an intron of the TGI, said BC comprising a barnase coding sequence, which is operably linked to an embryo/germination specific promoter; and an externally controllable recovering construct (RC) being able to recover the functions blocked by the BC, said RC comprising a barstar coding sequence which is operably linked to a heat shock promoter.

2. The mechanism according to claim 1, wherein the BC and the RC are located in different chromosomes.

3. The mechanism according to claim 1, wherein the BC and the RC are located in same inserts.

4. The mechanism according to claim 1, wherein the barnase is encoded by a synthetic nucleotide sequence comprising SEQ ID NO:1.

5. The mechanism according to claim 1, wherein the barstar is encoded by a synthetic nucleotide sequence comprising SEQ ID NO:2.

6. The mechanism according to claim 1, wherein the BC and the TGI are positioned in different directions.

7. The mechanism according to claim 1, wherein the BC and TGI are positioned in same direction and are sharing a polyadenylation site.

8. The mechanism according to claim 1, wherein the embryo/germination specific promoter is a cysteine endoDeDtidase (SH-EP) promoter.

9. The mechanism according to claim 1, wherein the TGI is driven by an inducible or constitutive promoter.

10. A complex of DNA constructs comprising: a TGI encoding desired gene products; a BC having a capacity to block at least one molecular or physiological function essential for development or reproduction of a transgenic plant containing said BC, thereby leading to death or incapacity of sexual reproduction, said BC being inserted fully into an intron of the TGI, said BC comprising a barnase coding sequence which is operably linked to an embryo/germination specific promoter; and an externally controllable RC being able to recover the functions blocked by the BC, said RC comprising a barstar coding sequence which is operably linked to a heat shock promoter.

11. The complex of DNA constructs according to claim 10, wherein the BC and the RC are located in different chromosomes.

12. The complex of DNA constructs according to claim 10, wherein the BC and the RC are located in same inserts.

13. The complex of DNA constructs according to claim 10, wherein the barnase is encoded by a nucleotide sequence comprising the SEQ ID NO:1.

14. The complex of DNA construct according to claim 10, wherein the barstar is encoded by a nucleotide sequence comprising the SEQ ID NO:2.

15. The complex of DNA constructs according to claim 10, wherein the BC and the TGI are in different directions.

16. The complex of DNA constructs according to claim 10, wherein the BC and TGI are positioned in same direction and share a polyadenylation site.

17. The complex of DNA constructs according to claim 10, wherein the embryo/germination specific promoter is an SH-EP promoter.

18. The complex of DNA constructs according to claim 10, wherein the TGI is driven by an inducible or constitutive promoter.

19. A transgenic plant comprising the complex of DNA constructs according to claim 10.

20. A transgenic cell line comprising the complex of DNA constructs according to claim 10.

Details for Patent 7,238,853

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Unicrop Ltd (Helsinki, FI) 2039-02-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Unicrop Ltd (Helsinki, FI) 2039-02-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Unicrop Ltd (Helsinki, FI) 2039-02-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Johnson and Johnson
Medtronic
Harvard Business School
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.